Clinical trials: Blood Plasma Therapy
Lyphoma, B-Cell, Leukemia, B-cell
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Background: Gene therapy is a way to treat or prevent disease using genes. It is monitored very closely by regulators because there can be long-term, unexpected side effects.
- Conditions
- Lyphoma, B-Cell, Leukemia, B-cell, Multiple Myeloma, Hematologic Malignancies
- Trial name
- NCT02473757
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Bone Marrow Transplantation, Hematopoietic Stem Cells
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
This is a pilot study to evaluate the efficacy of hyperbaric oxygen therapy (HBO2) for mobilizing hematopoietic progenitor cells from bone marrow to blood.
- Conditions
- Bone Marrow Transplantation, Hematopoietic Stem Cells, Multiple Myeloma, Lymphoma
- Trial name
- NCT02682953
- Testing
- Neupogen, Hyperbaric oxygen therapy, Plerixafor
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Multiple Myeloma, Refractory, Multiple Myeloma in Relapse
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients
This is a single arm, open-label, multicenter phase I study to assess the safety, tolerability and preliminary efficacy of autologous T cells transduced with a specific γδTCR, i.e.
- Conditions
- Multiple Myeloma, Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
- Trial name
- NCT04688853
- Testing
- TEG002
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Gadeta B.V.
HIV Infections
Long-Term Supervised Treatment Interruption in HIV-Infected Patients
This trial is aimed at studying the safety of long term supervised treatment interruption in HIV infected patients with CD4 over 350/mm3 and plasma HIV RNA under 50 000/mL.
- Trial name
- NCT00118677
- Testing
- Treatment interruption
- Where
- France
- Volunteers
- 130 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Multiple Myeloma
UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment
The purpose of this study is to evaluate the effect of Ixazomib on inducing osteoblast activation as measured by bone markers and imaging in patients with relapsed/refractory myeloma.
- Trial name
- NCT02499081
- Testing
- Ixazomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
This phase II MATCH treatment trial tests how well crizotinib works in treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes, or distant…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06357975
- Testing
- Biopsy Procedure, Biospecimen Collection, Crizotinib
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Erectile Dysfunction
Clinical Trial to Evaluate the Efficacy of Intracavernosal Infusion of PRP vs PPP for the Erectile Dysfunction.
Randomized, double-blind clinical trial to evaluate efficacy, feasibility and safety with two groups in a 1:1 ratio; where the control group corresponds to patients who will receive Platelet Poor plasma and an experimental group…
- Trial name
- PRePED (NCT04502875)
- Testing
- PRP, PPP
- Where
- Spain
- Volunteers
- 52 people
- Sponsor
- Puerta de Hierro University Hospital
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
This randomized phase III trial studies lenalidomide to see how well it works compared to a placebo in treating patients with multiple myeloma who are undergoing autologous stem cell transplant.
- Conditions
- DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT00114101
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 140 sites in United States
- Volunteers
- 460 people
- Sponsor
- National Cancer Institute (NCI)
Femoroacetabular Impingement
Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement
The purpose of this study is to compare the clinical response of intra-articular platelet rich plasma (PRP) versus corticosteroid injection in patients affected by femoroacetabular impingement (FAI).
- Trial name
- NCT02920177
- Testing
- platelet-rich plasma injection, Kenalog 10 MG/ML Injectable Suspension
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Michigan
Pilonidal Disease, Pilonidal Sinus
Effect of Platelet Rich Plasma (PRP) on Healing Time in Patients Following Pilonidal Sinus Surgery
Our study was planned as a prospective controlled randomized study. The study was started after the ethics committee approval received from Dışkapı Yıldırım Beyazıt Training and Research Hospital. (23.08.2021 118/01).
- Trial name
- NCT06206330
- Testing
- Platelet rich plasma
- Where
- Turkey (Türkiye)
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- İsmail Oskay Kaya
Epicondylitis
Platelet Rich Plasma (PRP) in Chronic Epicondylitis
Background Tendinopathy is a difficult problem to manage and can result in significant patient morbidity. Currently, the clinical use of PRP in painful tendons is widespread but its efficacy remains controversial.
- Trial name
- B-PRPtendon (NCT01945528)
- Testing
- US-guided tenotomy with PRP, US-guided tenotomy with lidocaine
- Where
- 2 sites in Spain
- Volunteers
- 86 people
- Sponsor
- Jose Ignacio Martin
Food Allergy
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
This study is researching an experimental drug called linvoseltamab combined with another drug called dupilumab. The study is looking at patients who have severe IgE-mediated food allergy.
- Trial name
- NCT06369467
- Testing
- linvoseltamab, dupilumab
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Regeneron Pharmaceuticals
Bone Metastasis, Cancer Pain
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.
- Trial name
- NCT02609828
- Testing
- Tanezumab
- Where
- 89 sites in Argentina, Australia and 14 more
- Volunteers
- 156 people
- Sponsor
- Pfizer
Burns
Autologous Platelets Concentrate and Autologous Thrombin for the Treatment of Deep Burn Trauma
Deep skin burn injuries, especially extensive deep burns or/and deep burns extending on the face, hands, feet, genitalia and perineum, remain one of the most challenging therapeutic problems.
- Trial name
- NCT01383187
- Testing
- DE graft and PRP concentrate, DE graft
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- University Hospital Ostrava
Chemotherapy-induced Symptomatic Anemia, Solid Tumors
Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
The main aim of this study is to observe correction of the hemoglobin level in the patients under chemotherapy, treated with epoetin alfa biosimilar and presenting with a solid tumor or a lymphoma or a myeloma.
- Conditions
- Chemotherapy-induced Symptomatic Anemia, Solid Tumors, Malignant Hemopathies, Lymphomas
- Trial name
- ORHEO (NCT02140736)
- Testing
- Epoetin biosimilar
- Where
- 172 sites in France
- Volunteers
- 2,333 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Stage II Multiple Myeloma, Stage III Multiple Myeloma
Aflibercept for Relapsed Multiple Myeloma
This phase II trial is studying the side effects and how well aflibercept works in treating patients with stage II or stage III multiple myeloma that has relapsed or not responded to previous treatment.
- Trial name
- NCT00437034
- Testing
- aflibercept
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Allogeneic Stem Cell Transplantation
Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant
Most patients with multiple myeloma (MM) die due to relapse resistant to current treatment, including treatment with anti-B cell maturation antigen (BCMA) CAR-T cells.
- Trial name
- CARTemis-1 (NCT05982275)
- Testing
- CARTemis-1
- Where
- 5 sites in Spain
- Volunteers
- 25 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC
Liquid Biopsy Based NGS in Newly Diagnosed NSCLC
This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC, Non-Squamous Non-Small Cell Neoplasm of Lung
- Trial name
- iNUDGE (NCT05853887)
- Testing
- iNUDGE
- Where
- 6 sites in United States
- Volunteers
- 260 people
- Sponsor
- Charu Aggarwal
Multiple Myeloma
PRospective Multiple Myeloma Impact Study
This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.
- Trial name
- PROMMIS (NCT02911571)
- Testing
- MMprofiler SKY92 gene signature
- Where
- 9 sites in United States
- Volunteers
- 250 people
- Sponsor
- SkylineDx
Multiple Myeloma
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma
This is an open-label, multicenter, Phase 1/2 study to determine the safety and efficacy of JCARH125, a CAR T-cell product that targets B-cell maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple…
- Trial name
- EVOLVE (NCT03430011)
- Testing
- JCARH125, JCARH125 + anakinra
- Where
- 20 sites in United States
- Volunteers
- 165 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.